Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
41 hedge funds and large institutions have $188M invested in Unity Biotechnology in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.03% more ownership
Funds ownership: 0% → 3.03% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$55.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.8M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$24.6M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.1M |
| 5 |
NTC
NF Trinity Capital
Central,
Hong Kong
|
+$8.89M |
Top Sellers
UBX Hedge Fund Activity: Q2 2018 in Review
41 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2018, worth a combined $188M.
Buyers outnumbered sellers: 41 funds opened new UBX positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $55.6M.
- 41 institutional investors held Unity Biotechnology (UBX) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $188M of Unity Biotechnology stock for Q2 2018.
- 41 funds opened new Unity Biotechnology positions in Q2 2018 and 0 closed out, a net change of +41 holders.
- The largest Unity Biotechnology buyer in Q2 2018 was Baillie Gifford & Co, an estimated $55.6M added.
Based on aggregated 13F filings for Q2 2018.